Research

Principal Investigator

National Natural Science Foundation of China (×1)

Open Funding Project of National Key Laboratory (×1)

Natural Science Basic Research Plan in Shaanxi Province of China (×1)

Xidian University Specially Funded Project for Interdisciplinary Exploration (×1)

Fundamental Research Funds for the Central Universities (×4)

Enterprise Collaborative Project (×1)

Participated

National Natural Science Foundation of China (×5)

Selected Publications

[1] Yun Zeng, Taotao Dou, Lei Ma, and Jingwen Ma*. Biomedical photoacoustic imaging for molecular detection and disease diagnosis: “always-on” and “turn-on” probes. Adv. Sci., 2022, 9(25), 2202384. 

[2] Yun Zeng*, Rachel L. Nixon, Wenyan Liu, and Risheng Wang*. The applications of functionalized DNA nanostructures in bioimaging and cancer therapy. Biomaterials, 2021, 268, 120560. 

[3] Yun Zeng, Huifang Liu, Jingwen Ma, Ke Li, Pang Chang, Chenying Wang, Lei Li, Dan Chen, Changhu Liu, Na Li*, Wenhua Zhan*, and Yonghua Zhan*. Cobalt ferrite-gossypol coordination nanoagents with high photothermal conversion efficiency sensitizing chemotherapy against Bcl-2 to induce tumor apoptosis. Small, 2023, 19(34), 2300104. 

[4] Yun Zeng, Yonghua Zhan*, Xinyue Liu, Jingwen Ma, Huifang Liu, Hanrui Li, Tong Yi, Qingxia Zhu, Getao Du, Linfei Zhao, Dan Chen, and Xueli Chen*. Highly efficient chemo/photothermal therapy alleviating tumor hypoxia against cancer and attenuate liver metastasis in vivo. Chem. Eng. J., 2022, 448, 137724. 

[5] Peng Chang, Yingying Guo, Dan Chen, Ke Li, Wei Wang, Zhihua Yang, Jingwen Ma*, Yun Zeng*, Wenhua Zhan*, Yonghua Zhan*. High-temperature PTT/CDT coordination nanoplatform realizing exacerbated hypoxia for enhancing hypoxia-activated chemotherapy to overcome tumor drug resistance. J. Nanobiotechnol., 2024, 22, 374. 

[6] Yun Zeng, Linfei Zhao, Ke Li, Jingwen Ma, Dan Chen, Changhu Liu, Wenhua Zhan*, and Yonghua Zhan*. Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia. Nano Res., 2023, 16(7), 9859-9872. 

[7] Yun Zeng, Peng Chang, Jingwen Ma, Ke Li, Chunhong Zhang, Yingying Guo, Hanrui Li, Qingxia Zhu, Huifang Liu, Wenjing Wang, Yuwei Chen, Dan Chen, Xu Cao*, and Yonghua Zhan*. DNA origami-anthraquinone hybrid nanostructures for in vivo quantitative monitoring of the progression of tumor hypoxia affected by chemotherapy. ACS Appl. Mater. Interfaces, 2022, 14(5), 6387-6403. 

[8] Jingwen Ma*, Na Li, Jingjian Wang, Zhe Liu, Yulong Han, and Yun Zeng*. In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms. Exploration, 2023, 3(5), 20220161. 

[9] Yun Zeng, Tong Yi, Jingwen Ma, Ming Han, Xinyi Xu, Dan Chen, Xueli Chen, Risheng Wang, and Yonghua Zhan*. Precisely controlled polydopamine-mediated antibacterial system: mathematical model of polymerization, prediction of antibacterial capacity, and promotion of wound healing. Nanotechnology, 2022, 33(45), 455102. 

[10] Yun Zeng, Jiajun Liu, Shuo Yang, Wenyan Liu, Liang Xu, and Risheng Wang*. Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures. J. Mater. Chem. B, 2018, 6(11), 1605-1612. (Front Cover, 2018 Journal of Materials Chemistry B HOT Papers)  

Daocheng Wu, Jingwen Ma, Youshen Wu, Yun Zeng, Shihong Shen. CN 201510777717.1

Daocheng Wu, Ke Li, Jiajun Liu, Hao Liu, Yun Zeng. CN 201410668713.5

(1) Chinese Biomaterials Congress: 2023 (Chongqing), 2020 (Youth Forum, Beijing), 2019 (Dalian), 

2017 (Nanchang), 2015 (Haikou) 

(2) Chinese Society of Biomedical Engineering Conference & Medical Innovation Summit: 2024 (Shenzhen), 

2023 (Suzhou);  2019 (Youth Forum, Dalian)

(3) Chinese Biophysics Conference: 2024 (Lanzhou)

(4) Chinese Chemical Society: 2019 (National Polymer Academic Paper Conference, Xi'an)

(5) International Symposium on Molecular Imaging (ISMI): 2019 (Zhuhai)

(6) Symposium on Innovative Polymers for Controlled Delivery (SIPCD): 2018 (5th, Suzhou)

(7) Ozark Biomedical Initiative Research Symposium (OBIRS): 2017 (Rolla, USA)

Dr. Jingwen Ma, Ninth Hospital of Xi'an